SG11201908721TA - Conjugation of a cytotoxic drug with bis-linkage - Google Patents
Conjugation of a cytotoxic drug with bis-linkageInfo
- Publication number
- SG11201908721TA SG11201908721TA SG11201908721TA SG11201908721TA SG 11201908721T A SG11201908721T A SG 11201908721TA SG 11201908721T A SG11201908721T A SG 11201908721TA SG 11201908721T A SG11201908721T A SG 11201908721TA
- Authority
- SG
- Singapore
- Prior art keywords
- street
- hangzhou
- zhejiang
- bildg
- international
- Prior art date
Links
- 230000021615 conjugation Effects 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 239000002254 cytotoxic agent Substances 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 0111111010 0111 °nolo OH H imomiono oimIE (10) International Publication Number WO 2018/185526 Al (51) International Patent Classification: C07D 417/14 (2006.01) A61P 31/00 (2006.01) (21) International Application Number: PCT/IB2017/051977 (22) International Filing Date: 06 April 2017 (06.04.2017) (25) Filing Language: English (26) Publication Language: English (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD [CN/CN]; Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA, Hangzhou, Zhejiang 310018 (CN). (72) Inventors: ZHAO, Robert Yongxin; 7Loring Street, 7Loring Street, Lexington, Massachusetts 02421 (US). HUANG, Yuanyuan; Room 401, Building 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YANG, Qingliang; Room 401, Building 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GAL Shun; Rm 303, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YE, Hangbo; Rm 402, Bldge 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). ZHAO, Linyao; Rm 403, Bldge 12, No. 260 Sixth Street, Hangzhou, Zhe- jiang 310018 (CN). YANG, Chengyu; Rm 402, Bldge 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). XU, Yifang; Rm 402, Bldg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GUO, Huihui; Rm 304, Bldg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). CHAO, Minjun; Rm 304, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). TONG, Qian- qian; Rm 302, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). LI, Wenjun; Rm 405, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). CAI, Xiang; Rm 304, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). ZHOU, Xiaomai; Rm 2006, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). XIE, Hongsheng; Rm 2005, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). JIA, Junxiang; Rm 301, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhe- jiang 310018 (CN). ZHU, Haifeng; Rm 305, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GUO, Zhixiang; Rm 102,Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GAO, Shuihong; Rm 305, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). WANG, Chunyan; Rm 305, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). LIN, Chen; Rm 301, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YANG, Yanlei; Rm 103, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YE, Zhicang; Rm 303, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). PENG, Jie; Rm 104, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). XU, Jun; Rm 301, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). ZUO, Xiaotao; Rm 402, Building 12, 260 Sixth Street, HEDA, Hangzhou, Zhejiang 310018 (CN). SU, Qingyu; Rm 303, Building 12, 260 Sixth Street, HEDA, Hangzhou, Zhejiang 310018 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.170) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) 1-1 (54) Title: CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE (57) : What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in 0 Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific \" manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease. C
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2017/051977 WO2018185526A1 (en) | 2017-04-06 | 2017-04-06 | Conjugation of a cytotoxic drug with bis-linkage |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908721TA true SG11201908721TA (en) | 2019-10-30 |
Family
ID=63712416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908721T SG11201908721TA (en) | 2017-04-06 | 2017-04-06 | Conjugation of a cytotoxic drug with bis-linkage |
Country Status (16)
Country | Link |
---|---|
US (4) | US20200069814A1 (en) |
EP (1) | EP3606922A4 (en) |
JP (2) | JP7218919B2 (en) |
KR (6) | KR102655301B1 (en) |
CN (1) | CN110621673A (en) |
AU (1) | AU2017408164B2 (en) |
BR (1) | BR112019020049A2 (en) |
CA (1) | CA3058712C (en) |
CL (1) | CL2019002858A1 (en) |
EA (1) | EA201992081A1 (en) |
IL (1) | IL269713B2 (en) |
MX (1) | MX2019011957A (en) |
NZ (1) | NZ757008A (en) |
PH (1) | PH12019502278A1 (en) |
SG (1) | SG11201908721TA (en) |
WO (1) | WO2018185526A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE061182T2 (en) | 2012-07-12 | 2023-05-28 | Hangzhou Dac Biotech Co Ltd | Conjugates of cell binding molecules with cytotoxic agents |
US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
ITUB20153803A1 (en) | 2015-09-22 | 2017-03-22 | Gd Spa | Machine for the production of cartridges for electronic cigarettes. |
CN109843327B (en) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | Antibody adjuvant conjugates |
PT3507291T (en) | 2016-09-02 | 2021-08-30 | Cyclerion Therapeutics Inc | Fused bicyclic sgc stimulators |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
BR112020010405A2 (en) | 2017-12-31 | 2020-11-24 | Hangzhou Dac Biotech Co., Ltd | side-chain-connected and side-chain-connecting conjugate compounds, side chains q1 and q2, d (tubulisin structure), w, l1, l2, v1 and v2, cell binding agent/molecule, tumor cell, pharmaceutical composition , and, chemotherapeutic and synergistic agents |
JP7429987B2 (en) * | 2018-07-05 | 2024-02-09 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Bridged pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof |
SG11202103424UA (en) * | 2018-10-12 | 2021-05-28 | Hangzhou Dac Biotech Co Ltd | Conjugation linkers containing 2,3-diaminosuccinyl group |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
EA202192137A1 (en) * | 2019-01-31 | 2021-10-25 | Ханчжоу Дэк Биотек Ко., Лтд | AMATOXY ANALOGUE CONJUGATE WITH BRANCHED LINKERS |
AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
JP2022532342A (en) | 2019-05-14 | 2022-07-14 | ニューベイション・バイオ・インコーポレイテッド | Anti-cancer nuclear hormone receptor targeting compound |
CN110054580A (en) * | 2019-05-22 | 2019-07-26 | 苏州百灵威超精细材料有限公司 | The preparation method of 4- (4-N- maleimide phenyl) butyric acid hydrazides hydrochloride |
CN114040779A (en) * | 2019-06-24 | 2022-02-11 | 杭州多禧生物科技有限公司 | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents |
WO2021011404A1 (en) * | 2019-07-12 | 2021-01-21 | Contrafect Corporation | Therapeutic protein formulations comprising antibodies and uses thereof |
US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
MX2022005034A (en) * | 2019-11-11 | 2022-05-16 | Cstone Pharmaceuticals Suzhou Co Ltd | Pharmaceutical combination and use thereof. |
TW202131930A (en) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | Anti-cancer nuclear hormone receptor-targeting compounds |
EP4090379A1 (en) * | 2020-01-13 | 2022-11-23 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
CN115666656A (en) * | 2020-01-13 | 2023-01-31 | 西纳福克斯股份有限公司 | Bilateral functionalization of antibodies by cycloaddition |
CN111297876B (en) * | 2020-01-16 | 2021-04-27 | 武汉理工大学 | Celecoxib micelle and honokiol micelle drug combination controlled release system and preparation method thereof |
TW202128131A (en) * | 2020-01-17 | 2021-08-01 | 大陸商信達生物制藥(蘇州)有限公司 | Recombinant anti-programmed cell death protein 1 and anti-cluster of differentiation antigen 137 bispecific antibody preparation and use thereof |
EP3862023A1 (en) * | 2020-02-05 | 2021-08-11 | Hangzhou DAC Biotech Co, Ltd | Conjugates of cell-binding molecules with cytotoxic agents |
CN111233949A (en) * | 2020-02-10 | 2020-06-05 | 天津科技大学 | Ganglioside GM3 and/or its analogue, synthetic method and application |
CN113925973A (en) * | 2020-07-14 | 2022-01-14 | 辽宁中健医药科技有限公司 | Polypeptide coupled drug, preparation method and application thereof |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
US20220306700A1 (en) | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN117355337A (en) * | 2021-03-29 | 2024-01-05 | 奥迪曼药业科技有限公司 | Protein-macromolecule conjugates and methods of use thereof |
CN115177740A (en) * | 2021-04-01 | 2022-10-14 | 安升(上海)医药科技有限公司 | Construction method and application of nucleic acid self-assembly mediated ADC (azodicarbonamide) medicament |
AU2022269568A1 (en) | 2021-05-03 | 2023-11-16 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN114213540B (en) * | 2022-02-22 | 2022-07-01 | 北京大学人民医院 | Antibody composition for immune typing of myeloid tumor and application thereof |
WO2024026099A1 (en) * | 2022-07-29 | 2024-02-01 | The Trustees Of The University Of Pennsylvania | Lymphatic targeted anti-coagulant for the prevention of lymphatic thrombosis |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3469580B2 (en) * | 1993-10-01 | 2003-11-25 | 帝国臓器製薬株式会社 | New peptide derivatives |
PT3192529T (en) * | 2009-04-08 | 2020-04-16 | Deutsches Krebsforsch | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
SG11201402686UA (en) * | 2011-12-05 | 2014-06-27 | Igenica Inc | Antibody-drug conjugates and related compounds, compositions, and methods |
JP2015510877A (en) * | 2012-03-09 | 2015-04-13 | ユーシーエル ビジネス パブリック リミテッド カンパニー | Chemical modification of antibodies |
WO2013173393A1 (en) * | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
FR3008408B1 (en) * | 2013-07-11 | 2018-03-09 | Mc Saf | NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY |
EP3307749A4 (en) * | 2015-06-15 | 2019-06-19 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers for conjugation |
CN113350518A (en) * | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | Conjugated bridge linkers to cell binding molecules |
US10292961B2 (en) * | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Disulfur bridge linkers for conjugation of a cell-binding molecule |
CA3209672A1 (en) * | 2016-02-04 | 2016-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
EP3445401A4 (en) * | 2016-04-20 | 2019-11-20 | Hangzhou DAC Biotech Co, Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
-
2017
- 2017-04-06 CA CA3058712A patent/CA3058712C/en active Active
- 2017-04-06 JP JP2019554514A patent/JP7218919B2/en active Active
- 2017-04-06 SG SG11201908721T patent/SG11201908721TA/en unknown
- 2017-04-06 EA EA201992081A patent/EA201992081A1/en unknown
- 2017-04-06 KR KR1020237016098A patent/KR102655301B1/en active IP Right Grant
- 2017-04-06 WO PCT/IB2017/051977 patent/WO2018185526A1/en unknown
- 2017-04-06 KR KR1020217031411A patent/KR20210125094A/en not_active IP Right Cessation
- 2017-04-06 NZ NZ757008A patent/NZ757008A/en unknown
- 2017-04-06 MX MX2019011957A patent/MX2019011957A/en unknown
- 2017-04-06 BR BR112019020049-5A patent/BR112019020049A2/en unknown
- 2017-04-06 KR KR1020217031412A patent/KR20210122318A/en active Application Filing
- 2017-04-06 AU AU2017408164A patent/AU2017408164B2/en active Active
- 2017-04-06 KR KR1020237016097A patent/KR20230074284A/en not_active Application Discontinuation
- 2017-04-06 KR KR1020197029324A patent/KR20190141660A/en not_active Application Discontinuation
- 2017-04-06 US US16/488,764 patent/US20200069814A1/en active Pending
- 2017-04-06 EP EP17904588.5A patent/EP3606922A4/en active Pending
- 2017-04-06 CN CN201780088370.7A patent/CN110621673A/en active Pending
- 2017-04-06 KR KR1020217031413A patent/KR20210122319A/en active Application Filing
-
2019
- 2019-09-26 IL IL269713A patent/IL269713B2/en unknown
- 2019-10-03 PH PH12019502278A patent/PH12019502278A1/en unknown
- 2019-10-06 CL CL2019002858A patent/CL2019002858A1/en unknown
-
2021
- 2021-07-28 US US17/387,205 patent/US20210369855A1/en active Pending
- 2021-07-30 US US17/390,064 patent/US20230001001A1/en active Pending
- 2021-07-30 US US17/389,922 patent/US20210393790A1/en active Pending
-
2023
- 2023-01-19 JP JP2023006257A patent/JP2023061938A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ757008A (en) | 2022-04-29 |
EA201992081A1 (en) | 2020-01-21 |
EP3606922A4 (en) | 2021-03-03 |
MX2019011957A (en) | 2019-11-07 |
EP3606922A1 (en) | 2020-02-12 |
US20210393790A1 (en) | 2021-12-23 |
JP2023061938A (en) | 2023-05-02 |
KR102655301B1 (en) | 2024-04-08 |
JP2020516595A (en) | 2020-06-11 |
AU2017408164A1 (en) | 2019-10-03 |
KR20210122318A (en) | 2021-10-08 |
KR20210125094A (en) | 2021-10-15 |
JP7218919B2 (en) | 2023-02-09 |
WO2018185526A1 (en) | 2018-10-11 |
US20210369855A1 (en) | 2021-12-02 |
KR20230074284A (en) | 2023-05-26 |
CA3058712A1 (en) | 2018-10-11 |
BR112019020049A2 (en) | 2020-05-12 |
PH12019502278A1 (en) | 2020-07-06 |
CL2019002858A1 (en) | 2020-09-04 |
AU2017408164B2 (en) | 2021-02-25 |
KR20210122319A (en) | 2021-10-08 |
IL269713B2 (en) | 2023-08-01 |
US20200069814A1 (en) | 2020-03-05 |
CA3058712C (en) | 2023-04-18 |
IL269713A (en) | 2019-11-28 |
KR20230074285A (en) | 2023-05-26 |
CN110621673A (en) | 2019-12-27 |
IL269713B1 (en) | 2023-04-01 |
KR20190141660A (en) | 2019-12-24 |
US20230001001A1 (en) | 2023-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908721TA (en) | Conjugation of a cytotoxic drug with bis-linkage | |
SG11201807652SA (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
SG11201807472TA (en) | Amanitin conjugates | |
SG11201811448RA (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201806594QA (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | |
SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201807185UA (en) | Modified hyaluronic acid, method for making same and uses thereof | |
SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201811205PA (en) | Polysiloxane based aerogels | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
SG11201909311TA (en) | Triterpene saponin synthesis, intermediates and adjuvant combinations | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201909841RA (en) | Antitumoral compounds | |
SG11201407261XA (en) | Oligonucleotide chelate complex methods | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
SG11201807768XA (en) | A polysiloxane hydrophobic coating material |